Chuyển sang chế độ ngoại tuyến với ứng dụng Player FM !
Treatment of Advanced Urothelial Carcinoma – A Discussion of EV-301
Manage episode 331831142 series 2812899
Welcome to our podcast episode on the treatment of urothelial carcinoma. In this episode, hosted by Anna Christofides, we discuss updated results of the Phase 3 EV-301 trial, presented at ASCO 2022, that examined the efficacy and safety of Enfortumab Vedotin, or EV, versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma.
Our Guest:
Our guest for this episode is Dr Nimira Alimohamed, Medical Oncologist and Clinical Associate Professor of Medicine at the University of Calgary and Medical Oncologist at the Tom Baker Cancer Centre in Calgary, Alberta.
This podcast episode was sponsored by Seagen Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
64 tập
Manage episode 331831142 series 2812899
Welcome to our podcast episode on the treatment of urothelial carcinoma. In this episode, hosted by Anna Christofides, we discuss updated results of the Phase 3 EV-301 trial, presented at ASCO 2022, that examined the efficacy and safety of Enfortumab Vedotin, or EV, versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma.
Our Guest:
Our guest for this episode is Dr Nimira Alimohamed, Medical Oncologist and Clinical Associate Professor of Medicine at the University of Calgary and Medical Oncologist at the Tom Baker Cancer Centre in Calgary, Alberta.
This podcast episode was sponsored by Seagen Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
64 tập
Tất cả các tập
×Chào mừng bạn đến với Player FM!
Player FM đang quét trang web để tìm các podcast chất lượng cao cho bạn thưởng thức ngay bây giờ. Đây là ứng dụng podcast tốt nhất và hoạt động trên Android, iPhone và web. Đăng ký để đồng bộ các theo dõi trên tất cả thiết bị.